Keynote comment: reimbursement for molecularly targeted anticancer agents.
Tirelli
Umberto
U
de Castro
Gilberto
G
Awada
Ahmad
A
D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D017277:Drug Approval; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D052138:Genes, Neoplasm; D006801:Humans; D007349:Insurance, Health, Reimbursement; D008967:Molecular Biology; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology
D000970:Antineoplastic Agents